Morepen Laboratories Ltd Share Price
As on 13 June 2026 at 02:32 IST
Net profit declined 69% to ₹11 crores, compared to ₹36 crores in Q1 FY25. Total income in Q1 FY26 declined 6% to ₹430 crores from ₹459 crores in the same period last year.
About Morepen Laboratories Ltd
Morepen Laboratories Limited is a pharmaceutical company in India. It specializes in the manufacturing, production, development, and marketing of APIs, branded and generic formulations, and home health products. Founded in 1984, the company has been in business for decades. Headquartered in New Delhi, India, Morepen Laboratories operates within the healthcare sector, specifically in pharmaceuticals and biotechnology. Its main products include APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-gout, and anti-malarial drugs. While it is not the biggest player in the industry, Morepen has a significant presence in the global pharmaceuticals market. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
3.28%
Over 6 Months
14.06%
Over 1 Year
-29.81%
Over 3 Years
74.82%
Morepen Laboratories Ltd Summary
Close ₹47.29
Open ₹49.25
High ₹49.60
Low ₹46.94
Volume 1,12,76,503
Net Turnover (in Cr) ₹54.34
52Wk High ₹70.50
52Wk Low ₹33.05
52Wk High / Low
33.05
70.50
Morepen Laboratories Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹2,591.27
EPS (TTM) 1.19
Book Value (BV) 22.68
Div. Yield 0.42 %
P/E (TTM) 39.07
Price/Book Value 2.08
Delivery % 23.43 %
Face Value 2
Key Ratios
PE Ratio 25.86
PB Ratio 2.22
EV to Sales 1.72
PEG Ratio -1.75
ROA 7.73
ROE 9.81
Debt-Equity 0.06
Net Profit Margin 6.53
Operating Profit Margin 10.88
Morepen Laboratories Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,829.94 | 1,704.40 | 1,423.66 | 1,557.13 | 1,200.13 |
| Total Expenses | 1,674.83 | 1,568.99 | 1,367.91 | 1,430.43 | 1,101.61 |
| Profit Before Tax | 155.11 | 135.42 | 55.76 | 126.70 | 98.51 |
| Profit After Tax | 118.02 | 96.62 | 38.68 | 101.68 | 97.09 |
| Operating Profit After Depreciation | 163.45 | 139.13 | 57.74 | 119.34 | 100.30 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 488.51 | 307.35 | 266.97 | 251.80 | 224.52 |
| Total Non Current Assets | 618.73 | 404.16 | 354.33 | 335.75 | 331.36 |
| Total Current Assets | 1,159.37 | 889.04 | 756.16 | 734.30 | 526.79 |
| Total Assets | 1,778.10 | 1,293.21 | 1,110.50 | 1,070.05 | 858.15 |
| Total Shareholder's Fund | 1,156.23 | 847.23 | 752.91 | 578.56 | 424.75 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 32.06 | 73.37 | -91.17 | -60.24 | 50.83 |
| Net Cash Used In Investing Activities | -321.51 | -83.30 | -46.51 | -31.68 | -70.35 |
| Net Cash Used In Financing Activities | 299.89 | 5.20 | 143.54 | 66.33 | 47.27 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,570.25 | 1,550.16 | 1,344.64 | 1,459.50 | 1,124.20 |
| Total Expenses | 1,432.67 | 1,401.18 | 1,281.60 | 1,333.96 | 1,029.95 |
| Profit Before Tax | 137.59 | 148.98 | 63.04 | 125.54 | 94.25 |
| Profit After Tax | 101.58 | 110.94 | 46.24 | 101.06 | 94.25 |
| Operating Profit After Depreciation | 144.69 | 152.48 | 65.02 | 118.18 | 96.04 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 365.87 | 216.54 | 170.82 | 156.11 | 144.02 |
| Total Non Current Assets | 614.42 | 436.40 | 374.69 | 356.50 | 354.71 |
| Total Current Assets | 1,106.78 | 842.91 | 730.85 | 676.76 | 492.79 |
| Total Assets | 1,721.20 | 1,279.31 | 1,105.54 | 1,033.26 | 847.50 |
| Total Shareholder's Fund | 1,181.50 | 889.02 | 780.11 | 598.17 | 444.97 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 29.08 | 77.36 | -102.12 | -68.87 | 49.31 |
| Net Cash Used In Investing Activities | -280.42 | -83.60 | -36.20 | -22.64 | -69.09 |
| Net Cash Used In Financing Activities | 260.47 | 0.28 | 144.20 | 66.41 | 47.46 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 484.72 | 484.16 | 411.58 | 425.24 | 465.85 |
| Total Expenses | 460.27 | 437.85 | 380.88 | 401.06 | 423.61 |
| Profit Before Tax | 23.28 | 35.42 | 45.71 | 15.52 | 25.71 |
| Profit After Tax | 15.70 | 27.50 | 41.04 | 11.41 | 20.31 |
| Operating Profit after Depreciation | 32.91 | 50.12 | 35.34 | 28.59 | 46.85 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 462.81 | 457.57 | 369.53 | 391.28 | 381.94 |
| Total Expenses | 439.50 | 415.69 | 341.61 | 372.33 | 351.78 |
| Profit Before Tax | 27.63 | 31.41 | 18.86 | 11.35 | 17.31 |
| Profit After Tax | 20.12 | 23.50 | 14.38 | 8.06 | 11.91 |
| Operating Profit after Depreciation | 32.13 | 45.81 | 32.57 | 23.04 | 33.30 |
Morepen Laboratories Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 46.29
S2 45.28
S3 43.63
Pivot 47.94
R1 48.95
R2 50.60
R3 51.61
Moving Average
20 SMA 44.21
50 SMA 42.38
100 SMA 40.47
200 SMA 43.42
Morepen Laboratories Ltd Corporate Actions
Morepen Laboratories Ltd
₹0.2/Share
Announcement Date 29 Aug 2025
Record Date 30 Aug 2025
Div Yield 10%
Morepen Laboratories Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,794.30 | ₹4,30,512.67 |
| Divis Laboratories Ltd | ₹6,651.25 | ₹1,76,569.79 |
| Torrent Pharmaceuticals Ltd | ₹4,570 | ₹1,54,669.57 |
| Cipla Ltd | ₹1,383 | ₹1,11,725.01 |
| Zydus Lifesciences Ltd | ₹1,105.65 | ₹1,11,254.26 |
Morepen Laboratories Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Bandhan BSE Healthcare Index Fund | 0.10% |
| Motilal Oswal BSE 1000 Index Fund | 0.01% |
Morepen Laboratories Ltd News
Board of Morepen Laboratories recommends final dividend
Of Rs 0.2 per share
27 May 2026, 11:06 am
Morepen Laboratories revises board meeting date
To 26 May 2026
22 May 2026, 12:35 pm
Morepen Laboratories schedules board meeting
On 22 May 2026
16 May 2026, 02:15 pm
Morepen Laboratories' Masulakhanna facility clears USFDA inspection
17 Apr 2026, 03:10 pm
Morepen Laboratories repays bank facilities worth Rs 79 cr
11 Mar 2026, 05:56 pm
Morepen Laboratories Ltd Stock Analysis
- Annual revenue for Morepen Laboratories Ltd increased by 1.30% to ₹1,570.25 crore in FY 2025 from ₹1,550.16 crore in FY 2024.
- Annual Net Profit for Morepen Laboratories Ltd decreased by 8.44% to ₹101.58 crore in FY 2025 from ₹110.94 crore in FY 2024.
- Promoter Shareholding in Morepen Laboratories Ltd remains unchanged by 0.00% in the most recent quarter, from 35.65% in December 2025 to 35.65% in March 2026.
- Morepen Laboratories Ltd delivered a 1-year return of -29.81% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
- Morepen Laboratories Ltd share price moved up by 3.49% from its previous close of INR ₹47.29. The latest Morepen Laboratories Ltd share price is INR ₹48.94.
- Morepen Laboratories Ltd share price today has been at a low of 48.21 and a high of 49.98. Over the past 52 weeks, the Morepen Laboratories Ltd share price has seen a low of 33.05 and a high of 70.50.
About Morepen Laboratories Ltd
Morepen Laboratories Limited is a prominent pharmaceutical company in India. The company specializes in the manufacturing, production, development, and marketing of a wide range of products. This includes Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and home health products. The company operates in the healthcare sector, which specifically include the pharmaceutical and biotechnology industries.
Founded in 1984, Morepen Laboratories has been in business for decades. The company's headquarters is located in New Delhi, India. In contrast, its additional offices and manufacturing facilities are in Himachal Pradesh and Gurgaon.
The company's main products include APIs for anti-histaminic, anti-asthmatic, anti-lipemic and anti-hypertensive drugs. They also provide APIs for anti-diabetic, anti-coagulant, anti-gout, anti-depressant, and anti-malarial drugs. Additionally, Morepen offers home diagnostic products such as blood glucose monitors, blood pressure monitors, and digital thermometers. Aside from the API and diagnostic products, the company provides over the counter (OTC) healthcare products. These OTC products are offered under the brand names Dr. Morepen and Gubb World.
While it is not the biggest player in the industry, Morepen has a significant presence in the global pharmaceuticals market. The company exports to over 75 countries and holds certifications from major regulatory authorities. This authority includes WHO GMP, USFDA, and EU GMP.
The promoter shareholding in Morepen Laboratories stands at 35.65%. Among these, Scope Credits and Financial Services Pvt. Ltd. and Concept Credits and Consultants Pvt. Ltd. hold 2.84% and 2.80% shares, respectively.
The registered office of Morepen Laboratories is located at Morepen Village, Nalagarh Road, Near Baddi, Distt. Solan, Himachal Pradesh - 173220, India. Its registrar is situated at T-34, 2nd Floor, Okhla Industrial Area, New Delhi 110020, Delhi. The company's management team includes key executives such as Mr. Sanjay Suri and Sushil Suri. Apart from them, there are other managerial promoters who have contributed to the success of the company. They are -
Morepen's influence on API manufacturing has been substantial, particularly in developing cost-effective production processes for essential medications. The company demonstrates its expertise in manufacturing APIs for various therapeutic categories. This includes anti-histaminic, anti-asthmatic, and anti-diabetic drugs. Their expertise has helped make critical medications more accessible and affordable. The company’s manufacturing process has also influenced the broader pharmaceutical industry by establishing benchmarks for quality and efficiency in API production.
In the domain of home diagnostics, Morepen has played a pivotal role in democratizing healthcare monitoring. Through its Dr. Morepen brand, the company has brought reliable and affordable diagnostic devices into millions of homes. These devices include blood glucose monitors and blood pressure monitors. This influence has contributed significantly to preventive healthcare and better disease management, which is particularly important in a country where healthcare infrastructure can be challenging to access.
The company's influence on quality standards in pharmaceutical manufacturing is noteworthy. Morepen has helped elevate Indian pharmaceutical manufacturing to global standards. This is because the company has secured certifications from prestigious regulatory authorities. This has influenced other domestic manufacturers to enhance their quality control processes and aspire for international certifications, improving the overall reputation of Indian pharmaceutical exports.
In terms of research and development, Morepen's influence extends to innovation in drug formulation and delivery systems. The company's continued investment in R&D has encouraged similar initiatives across the industry. This contributes to India's growing reputation as a hub for pharmaceutical innovation. Additionally, their work in developing new drug delivery systems and improving existing formulations has influenced how medications are administered and absorbed.
The company's influence on employment and skill development in the pharmaceutical sector is significant. Morepen has manufacturing facilities in Himachal Pradesh and other locations. Thus, it has created major employment opportunities and developed a skilled workforce in pharmaceutical manufacturing. This has influenced local economic development and created a talent pool that benefits the entire industry.
In the over-the-counter (OTC) healthcare segment, Morepen's influence is evident through its branded products under Dr. Morepen and Gubb World. These brands have influenced consumer behavior and awareness regarding self-care and preventive healthcare. Their marketing strategies and product positioning have helped shape how healthcare products are marketed to Indian consumers.
Morepen Labs impacts healthcare far beyond just making medicines. They focus on quality, innovation, and affordable healthcare products. Their home testing devices and low-cost medicines have improved public health. As healthcare changes, Morepen keeps growing and adapting, shaping both Indian and global pharmaceutical industries.
Founded in 1984, Morepen Laboratories has been in business for decades. The company's headquarters is located in New Delhi, India. In contrast, its additional offices and manufacturing facilities are in Himachal Pradesh and Gurgaon.
The company's main products include APIs for anti-histaminic, anti-asthmatic, anti-lipemic and anti-hypertensive drugs. They also provide APIs for anti-diabetic, anti-coagulant, anti-gout, anti-depressant, and anti-malarial drugs. Additionally, Morepen offers home diagnostic products such as blood glucose monitors, blood pressure monitors, and digital thermometers. Aside from the API and diagnostic products, the company provides over the counter (OTC) healthcare products. These OTC products are offered under the brand names Dr. Morepen and Gubb World.
While it is not the biggest player in the industry, Morepen has a significant presence in the global pharmaceuticals market. The company exports to over 75 countries and holds certifications from major regulatory authorities. This authority includes WHO GMP, USFDA, and EU GMP.
The promoter shareholding in Morepen Laboratories stands at 35.65%. Among these, Scope Credits and Financial Services Pvt. Ltd. and Concept Credits and Consultants Pvt. Ltd. hold 2.84% and 2.80% shares, respectively.
The registered office of Morepen Laboratories is located at Morepen Village, Nalagarh Road, Near Baddi, Distt. Solan, Himachal Pradesh - 173220, India. Its registrar is situated at T-34, 2nd Floor, Okhla Industrial Area, New Delhi 110020, Delhi. The company's management team includes key executives such as Mr. Sanjay Suri and Sushil Suri. Apart from them, there are other managerial promoters who have contributed to the success of the company. They are -
- Sukhcharan Singh
- Praveen Kumar Dutt
- Bhupender Raj Wadhwa
Influence of the Company
Morepen Laboratories has established itself as an influential force in the Indian and global pharmaceutical landscape since 1984. It has an extensive portfolio of APIs, branded formulations, and home health products. Thus, the company has significantly impacted healthcare accessibility and quality. Its influence extends beyond India's borders, reaching over 75 countries. As a result, the company has shaped pharmaceutical manufacturing standards and practices.Morepen's influence on API manufacturing has been substantial, particularly in developing cost-effective production processes for essential medications. The company demonstrates its expertise in manufacturing APIs for various therapeutic categories. This includes anti-histaminic, anti-asthmatic, and anti-diabetic drugs. Their expertise has helped make critical medications more accessible and affordable. The company’s manufacturing process has also influenced the broader pharmaceutical industry by establishing benchmarks for quality and efficiency in API production.
In the domain of home diagnostics, Morepen has played a pivotal role in democratizing healthcare monitoring. Through its Dr. Morepen brand, the company has brought reliable and affordable diagnostic devices into millions of homes. These devices include blood glucose monitors and blood pressure monitors. This influence has contributed significantly to preventive healthcare and better disease management, which is particularly important in a country where healthcare infrastructure can be challenging to access.
The company's influence on quality standards in pharmaceutical manufacturing is noteworthy. Morepen has helped elevate Indian pharmaceutical manufacturing to global standards. This is because the company has secured certifications from prestigious regulatory authorities. This has influenced other domestic manufacturers to enhance their quality control processes and aspire for international certifications, improving the overall reputation of Indian pharmaceutical exports.
In terms of research and development, Morepen's influence extends to innovation in drug formulation and delivery systems. The company's continued investment in R&D has encouraged similar initiatives across the industry. This contributes to India's growing reputation as a hub for pharmaceutical innovation. Additionally, their work in developing new drug delivery systems and improving existing formulations has influenced how medications are administered and absorbed.
The company's influence on employment and skill development in the pharmaceutical sector is significant. Morepen has manufacturing facilities in Himachal Pradesh and other locations. Thus, it has created major employment opportunities and developed a skilled workforce in pharmaceutical manufacturing. This has influenced local economic development and created a talent pool that benefits the entire industry.
In the over-the-counter (OTC) healthcare segment, Morepen's influence is evident through its branded products under Dr. Morepen and Gubb World. These brands have influenced consumer behavior and awareness regarding self-care and preventive healthcare. Their marketing strategies and product positioning have helped shape how healthcare products are marketed to Indian consumers.
Morepen Labs impacts healthcare far beyond just making medicines. They focus on quality, innovation, and affordable healthcare products. Their home testing devices and low-cost medicines have improved public health. As healthcare changes, Morepen keeps growing and adapting, shaping both Indian and global pharmaceutical industries.
FAQ’s
What is the share price of Morepen Laboratories Ltd today?
Morepen Laboratories Ltd share price as on 12 Jun 2026 is ₹ 48.94
What is the Market Cap of Morepen Laboratories Ltd?
The market cap of Morepen Laboratories Ltd stock is ₹2,591.27 Cr.
What is the PE Ratio of Morepen Laboratories Ltd?
The Price to Earnings (P/E) Ratio of Morepen Laboratories Ltd is 25.86
What is the PB Ratio of Morepen Laboratories Ltd?
The Price to Book (P/B) Ratio of Morepen Laboratories Ltd is 2.22
What is the 52 week high of Morepen Laboratories Ltd Share Price?
The 52 week high of Morepen Laboratories Ltd share price stands at ₹70.50
What is the 52 week low of Morepen Laboratories Ltd Share Price?
The 52 week low of Morepen Laboratories Ltd share price stands at ₹33.05
How can I buy shares of Morepen Laboratories Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Morepen Laboratories Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
